Partha Anbil

Life sciences organizations have an opportunity to move beyond patient-centered care and embrace a model that values lived experience, fosters collaboration, and positions patients as active contributors to research, treatment, and innovation.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Cloud-based IT technologies are a natural fit for patient-support hubs